December 1st 2021
Discussion of recent clinical trial updates in HER2-positive metastatic breast cancer and implications for managing 2 patient case scenarios.
November 30th 2021
Experts in gastrointestinal cancers review optimal treatment strategies for the management of metastatic colorectal cancer (mCRC).
November 22nd 2021
Expert hematologists provide insight on updates on the role of PI3K inhibitors in the treatment of relapsed/refractory MZL and FL.
November 10th 2021
Drs Arlene O. Siefker-Radtke and Scott T. Tagawa comment on opportunities for treating metastatic urothelial cancer with FGFR targeted therapies based on current trends in molecular testing and emerging therapies.
October 28th 2021
Practical perspectives on recent data and FDA approvals supporting novel agents that target EGFR exon 20 insertion mutations in non–small cell lung cancer.
October 27th 2021
Recommendations for managing HR-positive, HER2-negative metastatic breast cancer with CDK4/6 inhibitors and endocrine therapy.
October 11th 2021
This OncLive Insights features 3 experts who share their thoughts on how the treatment landscape of advanced NSCLC is evolving through use of comprehensive genetic sequencing to identify actionable biomarkers. They summarize how novel therapeutics which target driver alterations in ALK, ROS, RET, or NTRK can be leveraged to personalize and optimize management of advanced NSCLC, ultimately improving survival outcomes.
August 30th 2021
Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review current treatment strategies and challenges for the management of myelofibrosis and the evolving treatment landscape of the disease.
August 25th 2021
Through the lens of multidisciplinary management in breast cancer, experts share practical insight on the identification and management of interstitial lung disease.
August 20th 2021
An overview of neuroendocrine tumors and comprehensive insight on the novel targeted therapies that are improving outcomes for patients.
August 5th 2021
Key opinion leaders discuss disease management strategies and novel therapeutics in high-risk patients with myelodysplastic syndromes, focusing on therapeutic options and diagnostic criteria.
July 30th 2021
This OncLive Insights features 3 experts who elucidate treatment advances for patients with Chronic Lymphocytic Leukemia (CLL). Considering both the frontline and relapsed/refractory setting, these key opinion leaders share their perspectives on optimal risk stratification, molecular targets, and sequencing strategies given data from recent clinical trials.
July 27th 2021
This OncLive Insights features two oncologists who specialize in the treatment of Acute Lymphoblastic Leukemia (ALL). They discuss risk assessment, approaches to treatment of both Philadelphia chromosome positive (Ph+) and Ph- ALL, the factors they consider when choosing a treatment setting (community or tertiary academic center), use of MRD in ALL, sequencing therapies in the relapsed/refractory setting, and the role of CAR T-cell therapy in this patient population.
July 27th 2021
Considerations for using newer, novel-based combination regimens to treat patients with metastatic colorectal cancer based on strategies explored in recent clinical trials.
July 12th 2021
Key thought leaders in gastrointestinal oncology build a lively discussion on recent clinical trial updates on immuno-oncology-based combinations for the management of patients with metastatic gastric and gastroesophageal junction cancers and the implications for clinical practice.
June 4th 2021
Key opinion leaders discuss recent updates in treating relapsed or refractory multiple myeloma.
May 25th 2021
Recommendations for appropriately managing metastatic colorectal cancer with anti-EGFR therapy based on recent changes to cetuximab dosing.
May 4th 2021
Recommendations for sequencing therapies for triple-class refractory myeloma with options such as selinexor, belantamab mafodotin, or melflufen.
April 20th 2021
Experts in hematology and medical oncology, Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, discuss the current therapeutic options available for marginal zone lymphoma and follicular lymphoma and provide key insights into how the recent accelerated approval of umbralisib has impacted the treatment landscape.